Related Experiment Video
Updated: Jul 12, 2026
08:07
Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
Published on: April 7, 2023
Exposure-response analysis reveals that clinically important toxicity difference can exist between bioequivalent
Laszlo Tothfalusi1, Szilvia Speidl, Laszlo Endrenyi
1Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary.
British Journal of Clinical Pharmacology
|August 23, 2007
Summary
Therapeutically important differences may exist between bioequivalent carbamazepine (CBZ) tablets. Alternative pharmacokinetic metrics, like partial AUC, better predict adverse events than Cmax, suggesting a need for revised bioequivalence criteria.
Area of Science:
- Pharmacokinetics and Pharmacodynamics
- Drug Safety and Efficacy
- Regulatory Science
Background:
- Bioequivalence criteria aim to ensure drug product similarity.
- Carbamazepine (CBZ) is a narrow therapeutic index drug.
- Understanding absorption rate's impact on adverse effects is crucial.
Purpose of the Study:
- Assess if therapeutically important differences exist between bioequivalent carbamazepine (CBZ) tablets under current regulatory standards.
- Quantitatively evaluate the relationship between CBZ absorption rate and neurological adverse effects.
Main Methods:
- Reanalysis of a bioequivalence study by Olling et al.
- Development of a mixed-effect pharmacokinetic-pharmacodynamic (PK-PD) model.
- Sensitivity analysis of PK-PD model parameters.
Main Results:
- Neurological adverse effects showed rapid tolerance development (half-life ~2.29 h).
- Maximum concentration (Cmax) demonstrated poor sensitivity for predicting adverse events.
- Partial AUC was a more sensitive marker for early adverse events during absorption.
Conclusions:
- Acute tolerance to CBZ adverse effects must be considered in clinical and regulatory contexts.
- Partial AUC is a more sensitive indicator of adverse event risk than Cmax.
- Alternative PK metrics are proposed to replace tightened bioequivalence criteria for narrow therapeutic index drugs.
Related Concept Videos
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:16Bioequivalence Data: Statistical Interpretation
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.